ES2543280T3 - Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico - Google Patents

Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico Download PDF

Info

Publication number
ES2543280T3
ES2543280T3 ES10742690.0T ES10742690T ES2543280T3 ES 2543280 T3 ES2543280 T3 ES 2543280T3 ES 10742690 T ES10742690 T ES 10742690T ES 2543280 T3 ES2543280 T3 ES 2543280T3
Authority
ES
Spain
Prior art keywords
cells
astrocytes
brain
paclitaxel
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10742690.0T
Other languages
English (en)
Spanish (es)
Inventor
Isaiah J. Fidler
Sun-Jin Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
The University of Texas at Austin
Original Assignee
The University of Texas System
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42938154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2543280(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The University of Texas System, The University of Texas at Austin filed Critical The University of Texas System
Application granted granted Critical
Publication of ES2543280T3 publication Critical patent/ES2543280T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1077—Beam delivery systems
    • A61N5/1084—Beam delivery systems for delivering multiple intersecting beams at the same time, e.g. gamma knives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
ES10742690.0T 2009-08-10 2010-08-09 Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico Active ES2543280T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23268709P 2009-08-10 2009-08-10
US232687P 2009-08-10
PCT/US2010/044832 WO2011019630A2 (en) 2009-08-10 2010-08-09 Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors

Publications (1)

Publication Number Publication Date
ES2543280T3 true ES2543280T3 (es) 2015-08-17

Family

ID=42938154

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10742690.0T Active ES2543280T3 (es) 2009-08-10 2010-08-09 Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico

Country Status (27)

Country Link
US (2) US8999934B2 (enExample)
EP (1) EP2464218B1 (enExample)
JP (1) JP2013501791A (enExample)
KR (1) KR20120088665A (enExample)
CN (1) CN102510719B (enExample)
AU (1) AU2010282744B2 (enExample)
BR (1) BR112012003103A2 (enExample)
CA (1) CA2770397A1 (enExample)
CL (1) CL2012000333A1 (enExample)
DK (1) DK2464218T3 (enExample)
EA (1) EA023864B1 (enExample)
ES (1) ES2543280T3 (enExample)
HR (1) HRP20150890T1 (enExample)
HU (1) HUE026005T2 (enExample)
IL (1) IL217915A0 (enExample)
IN (1) IN2012DN01261A (enExample)
MA (1) MA33571B1 (enExample)
MX (1) MX2012001562A (enExample)
NZ (1) NZ598078A (enExample)
PL (1) PL2464218T3 (enExample)
PT (1) PT2464218E (enExample)
SG (1) SG178828A1 (enExample)
SI (1) SI2464218T1 (enExample)
TN (1) TN2012000054A1 (enExample)
TW (1) TWI483938B (enExample)
WO (1) WO2011019630A2 (enExample)
ZA (1) ZA201200980B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201309298A (zh) * 2011-02-04 2013-03-01 Actelion Pharmaceuticals Ltd 治療惡性神經膠質瘤之醫藥組合物
CA2840170A1 (en) * 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
HK1249052A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
WO2016144636A1 (en) * 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
CN116726183A (zh) 2015-08-03 2023-09-12 Enb治疗公司 用于治疗与etbr激活相关的癌症的组合物和方法
JP6996728B2 (ja) * 2016-01-07 2022-01-17 学校法人自治医科大学 グルコーストランスポーター１発現用アデノ随伴ウイルスベクター
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
WO2017209272A1 (ja) * 2016-06-03 2017-12-07 国立大学法人東京大学 がん転移阻害剤
CN109475524A (zh) 2016-06-06 2019-03-15 万春药业公司 用于减少中性粒细胞减少症的组合物和方法
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
SG11201908472VA (en) 2017-02-15 2019-10-30 Univ California Compositions and methods for activating nk cells
WO2019140324A1 (en) 2018-01-12 2019-07-18 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation
WO2019147615A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
CN109232546B (zh) 2018-09-25 2020-09-04 中国人民解放军总医院 一种嘧啶磺酰胺类衍生物的医药用途
PL3974421T3 (pl) 2019-05-22 2024-11-04 Wuxi Biocity Biopharmaceutics Co., Ltd. Krystaliczna postać związku sulfonamidu pirymidyny i sposób jego otrzymywania
CN112062857B (zh) * 2019-06-10 2024-08-09 鸿运华宁（杭州）生物医药有限公司 Eta抗体与bnp的融合蛋白质，及其药物组合物和应用
AU2020355109B2 (en) * 2019-09-25 2025-06-12 The Board Of Trustees Of The Leland Stanford Junior University Thalamic input to orbitofrontal cortex drives brain-wide, frequency-dependent inhibition mediated by GABA and zona incerta
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1693372A1 (en) 2000-12-18 2006-08-23 Actelion Pharmaceuticals Ltd. Novel Sulfamides and their use as endothelin receptor antagonists
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
ES2393117T3 (es) 2005-09-12 2012-12-18 Actelion Pharmaceuticals Ltd. Composición farmacéutica estable que comprende una pirimidina-sulfamida
MX2010008994A (es) 2008-02-20 2010-09-07 Actelion Pharmaceuticals Ltd Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.
TW201309298A (zh) 2011-02-04 2013-03-01 Actelion Pharmaceuticals Ltd 治療惡性神經膠質瘤之醫藥組合物

Also Published As

Publication number Publication date
MX2012001562A (es) 2013-01-29
EP2464218A2 (en) 2012-06-20
TWI483938B (zh) 2015-05-11
WO2011019630A2 (en) 2011-02-17
SG178828A1 (en) 2012-04-27
ZA201200980B (en) 2012-10-31
CL2012000333A1 (es) 2013-01-25
TN2012000054A1 (en) 2013-09-19
JP2013501791A (ja) 2013-01-17
WO2011019630A3 (en) 2011-06-03
EP2464218B1 (en) 2015-05-27
US20120144510A1 (en) 2012-06-07
CN102510719B (zh) 2015-07-22
AU2010282744A1 (en) 2012-03-22
EA023864B1 (ru) 2016-07-29
KR20120088665A (ko) 2012-08-08
CA2770397A1 (en) 2011-02-17
US20150352113A1 (en) 2015-12-10
PL2464218T3 (pl) 2015-12-31
TW201109315A (en) 2011-03-16
SI2464218T1 (sl) 2015-10-30
IN2012DN01261A (enExample) 2015-05-15
HK1171336A1 (en) 2013-03-28
IL217915A0 (en) 2012-03-29
NZ598078A (en) 2013-07-26
PT2464218E (pt) 2015-09-16
EA201270264A1 (ru) 2013-02-28
HRP20150890T1 (hr) 2015-09-25
CN102510719A (zh) 2012-06-20
AU2010282744B2 (en) 2014-08-28
MA33571B1 (fr) 2012-09-01
BR112012003103A2 (pt) 2016-04-19
US8999934B2 (en) 2015-04-07
DK2464218T3 (en) 2015-07-20
HUE026005T2 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
DK2464218T3 (en) Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic agent for chemotherapy
Wen et al. Cuproptosis enhances docetaxel chemosensitivity by inhibiting autophagy via the DLAT/mTOR pathway in prostate cancer
ES2632212T3 (es) miR-135 y composiciones que lo comprenden para el tratamiento de afecciones médicas asociadas con la serotonina
EP3106168A2 (en) Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer
Tseng et al. Caffeic acid phenethyl ester suppresses EGFR/FAK/Akt signaling, migration, and tumor growth of prostate cancer cells
ES2673209T3 (es) Procedimientos de tratamiento del cáncer colorrectal
Zhang et al. Angiotensin-converting enzyme inhibitors have adverse effects in anti-angiogenesis therapy for hepatocellular carcinoma
Wu et al. CDK12 inhibition upregulates ATG7 triggering autophagy via AKT/FOXO3 pathway and enhances anti-PD-1 efficacy in colorectal cancer
Li et al. Concurrent silencing of TBCE and drug delivery to overcome platinum-based resistance in liver cancer
Zhi et al. hERG1 is involved in the pathophysiological process and inhibited by berberine in SKOV3 cells
Liu et al. A novel near-infrared fluorescent hERG potassium channel probe for glioblastoma therapy and imaging
Florian et al. Cancer stem cells and malignant gliomas. From pathophysiology to targeted molecular therapy
Han et al. A tetrahedral DNA nanoplatform with ultrasound-triggered biomimetic nanocarriers for targeted siMCM2 delivery and reversal of imatinib resistance in gastrointestinal stromal tumors
Wang et al. Characterization of highly proliferative secondary tumor clusters along host blood vessels in malignant glioma
CN108704139A (zh) 一种具有协同作用的胰腺癌治疗药物组合
Lu et al. Neuron-glioma synaptic transmission amplified by free 19S proteasome-mediated AMPAR deubiquitination promotes tumor progression
HK1171336B (en) Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent
TWI923013B (zh) 透過影響癌細胞膜受體及源自其產生之胞外體治療癌症之組合物及方法
Tuan et al. Intravenous paclitaxel against metastasis of human gastric tumors of diffuse type
KR20170081232A (ko) 단기-작용성 항혈관신생 제제의 타이밍을 맞춘 투여를 통한 asm아제/세라마이드 경로의 활성화에 의한 화학요법에 대한 종양 반응의 향상
Zhou et al. Diffuse intrinsic pontine glioma: Translation of genomic knowledge to clinical practice
CN120285196A (zh) Smad1棕榈酰化调节剂在制备增强高级别浆液性卵巢癌顺铂敏感性药物中的用途
CN112168828A (zh) 一种egfr与cdk4/6小分子靶向药组合物及其应用
Jangra The synergistic effect of disulfiram with cisplatin in atypical teratoid/rhabdoid tumors (AT/RT)
Becker Molecular Mechanisms Underlying the Failures of Therapeutics in the Treatment of Malignant Glioma